Zacks Investment Research
19 Jun 2026, 16:41 UTC · 13w ago
Verdict
Headline takes no side. We score FUL +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
H. B. Fuller (FUL) currently has a Zacks Rank of #2 (Buy) and a Value grade of B.
More positive than 64% of claims this week
Novozymes A/S (NVZMY) currently has a Zacks Rank of #3 (Hold) and a Value grade of D.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 67% of claims this week
H. B. Fuller's forward P/E ratio is 13.57 and PEG ratio is 0.85, compared to Novozymes A/S's forward P/E of 24.55 and PEG of 1.11.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company has a Zacks Rank of #2 (Buy), a Value grade of B, and an improving earnings outlook.
More negative than 75% of ticker scores this week
The company has a Zacks Rank of #3 (Hold) and a Value grade of D, performing worse than FUL on key metrics.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1d ago
−24.1%
Price is moving against the score
$49.22 vs $64.86 close before publication (Jun 18) · not market-adjusted
FUL chart →
